A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

Herpes Zoster Clinical Trial

Official title:

A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients With Autoimmune Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01527383
• Other study ID #: V212-009
• Secondary ID: V212-0092011-002
• Status: Completed
• Phase: Phase 2
• Start date: February 21, 2012
• Est. completion date: February 26, 2013

Study information

• Verified date: January 2019
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study to evaluate the safety and immunogenicity of V212 vaccine in adults with autoimmune disease, including participants with rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, and other similar diseases. The primary hypothesis is that vaccination with V212 vaccine will elicit significant VZV-specific immune responses at approximately 28 days after vaccination 4. The statistical criterion for significance requires that the lower bound of the 2-sided 95% confidence interval of the geometric mean fold rise in vaccine recipients is >1.0.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 354
• Est. completion date: February 26, 2013
• Est. primary completion date: February 26, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with an autoimmune disease

• Clinically stable disease for at least 30 days before enrollment

• Not likely to undergo hematopoietic stem cell transplantation during the study period

• Receiving at least one parenteral or oral biologic agent, such as a Tumor Necrosis factor (TNF) alpha inhibitor, or a parenteral or oral non-biologic therapy, at a stable dose for at least 3 months, with no planned or anticipated changes

• History of varicella, antibodies to VZV, or residence for at least 30 years in a country with endemic VZV infection, or if participant is less than 30 years old, attended primary or secondary school in a country with endemic VZV infection

Exclusion Criteria:

• Prior history of Herpes Zoster (shingles) within 1 year before enrollment

• Prior varicella or zoster vaccine

• Active central nervous system lupus erythematosus requiring therapeutic intervention within 90 days of enrollment

• Prior or planned therapy containing rituximab or other anti-Cluster of Differentiation (CD) 20 monoclonal antibodies from 3 months before enrollment through 28 days postdose 4

• Systemic corticosteroid therapy, prednisone, or equivalent over 40 mg daily at the time of enrollment

Related Conditions & MeSH terms

• Autoimmune Diseases
• Herpes Zoster

Intervention

Biological:
• V212
V212 viral antigen for HZ
• Placebo
Placebo comparator to V212 vaccine

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

References & Publications (1)

Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, Zhao Y, Parrino J, Popmihajlov Z. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Control — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric Mean Fold Rise (GMFR) in Varicella-Zoster (VZV) Antibody Responses Measured by Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA)	Serum samples were tested for antibody response using a gpELISA. The GMFR is response at approximately 28 days postdose 4 / response predose on Day 1.	Baseline and ~28 days after Vaccination 4 (~Day 118)
Primary	GMFR in VZV Antibody Response Measured by VZV Interferon-gamma (IFN-g) Enzyme-linked Immunospot (ELISPOT) Assay	Serum samples were tested for activity using a VZV ELISPOT assay. The assay detects IFN-?-secreting, VZV-specific cells from peripheral blood mononuclear cells (PBMCs). The unit of measure of the assay is ELISPOT cell count / 10^6 PBMCs, and is expressed as geometric mean count (GMC). The GMFR is GMC at ~28 days after Vaccination 4 / GMC predose on Day 1.	Baseline and ~28 days after Vaccination 4 (~Day 118)
Primary	Percentage of Participants With a Serious Adverse Event	A serious adverse event (SAE) is defined as an adverse event that resulted in death, was life threatening, resulted in persistent or significant disability or incapacity, resulted in or prolonged a hospitalization, is a congenital anomaly or birth defect, is a cancer, was an overdose, or was an important medical event based on appropriate medical judgment. The percentage of participants with one or more SAE was assessed.	Up to ~28 days after Vaccination 4 (~Day 118)
Secondary	Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card	An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Vaccination Report Card (VRC)-prompted injection-site AEs were erythema, pain, and swelling. The percentage of participants with one or more VRC-prompted injection-site AE was assessed.	Up to Day 5 after any vaccination
Secondary	Percentage of Participants With a Systemic Adverse Event Prompted on the Vaccination Report Card	An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the study vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. VRC-prompted systemic AEs included non-injection-site varicella-like and HZ-like rashes. The percentage of participants with one or more VRC-prompted systemic AE was assessed.	Up to ~28 days after Vaccination 4 (~Day 118)
Secondary	Percentage of Participants With Elevated Temperature Prompted on the Vaccination Report Card	Elevated temperature is defined as =100.4 °F (=38.0 °C), oral equivalent. The percentage of participants with VRC-prompted elevated temperature was assessed.	Up to ~28 days after Vaccination 4 (~Day 118)